Special Delivery

Home ketamine sounds convenient. Before signing up, find out what they’re mailing you and who’s actually looking after you.

You’ve tried the antidepressant thing, maybe several times. You’re better than you were, but work still drags and the weekend’s still flat. Then a home ketamine offer shows up. Something other than another pill swap, without fitting clinic trips around work… yeah, that’s going to get your attention.

Before buying it, check what was actually studied and what they’re actually selling. An infusion in a clinic isn’t a direct test of the tablet in your mailbox. Calling them both ketamine doesn’t erase that difference.

Three different things all get called ketamine

Supervised IV ketamine. Regular racemic ketamine, the same molecule used in anesthesia, goes into a vein while somebody watches you. This was the early depression research: seven people completed one small double blind crossover study, and depression scores dropped within days of one infusion compared with saline [6]. That result came from a tiny supervised study, so don’t quote it as if they tested troches sent to somebody’s home.

Spravato, which is esketamine nasal spray. This has FDA approval for adults with treatment resistant depression, on its own or with an oral antidepressant. There’s a separate use for depressive symptoms in adults with major depression and acute suicidal thoughts or behavior, together with an oral antidepressant. That doesn’t mean it’s shown to prevent suicide or replace hospital care. You don’t take it home; it’s supervised, with at least two hours of monitoring afterward. [3]

Compounded racemic ketamine at home. A compounding pharmacy makes the troche or dissolving tablet, usually mailed after a telehealth prescription. FDA hasn’t approved ketamine for any psychiatric condition. Its 2023 alert said there’s no established psychiatric dose and raised the problem of oral or sublingual home use without a care team member there to watch you [4]. It also distinguishes these products from Spravato [4]. Don’t assume these are interchangeable because the pitch keeps repeating the word ketamine.

Compounded drugs don’t get FDA review for safety, effectiveness or quality before reaching you [5]. They aren’t automatically junk; some people need something an approved product doesn’t cover [5]. Just don’t assume there’s an approval stamp on the box because a clinician prescribed it.

Keep all three straight when somebody starts quoting results. Make them name the product, not just repeat “ketamine.”

What the home data actually shows

A 2024 paper followed 11,441 people in a telehealth home ketamine service who took four doses at home over four weeks [1]. The authors reported symptom improvement. That tells you something about people in that program, not what the next person to pay will get.

It doesn’t tell you how much improvement came from ketamine. There was no comparison group, no placebo and no fixed dose procedure [1]. You can’t separate the drug from expectations, time or whatever else changed that month without a control group. A big head count doesn’t solve that.

These were a commercial service’s records, and the authors included an employee and someone paid consulting fees [1]. Keep the connection in view. The events recorded in one program aren’t a universal estimate of your risk either.

There’s also a small absorption study that gets quoted about dosing under the tongue. It compared one specific wafer with an IV dose in eight healthy men, with the authors interested in pain treatment [2]. It tells you about that wafer. It doesn’t tell you how your pharmacy’s troche absorbs, kicks in, compares milligram for milligram or feels. It wasn’t even a depression study.

Make them explain the home treatment

I get the appeal of not driving back and forth for treatment. Before you decide it fits around work, get the appointment schedule and find out how the monitoring and follow up actually happen. Programs don’t all provide the same thing, and staying home doesn’t guarantee you won’t need time off.

The sources here don’t establish that a compounded home troche works as well as IV ketamine or Spravato. FDA’s alert says psychiatric ketamine dosing hasn’t been established [4]. Ask for the evidence behind this program’s treatment and advertised results. It doesn’t get to borrow another product’s success rate because they share part of a name.

There’s more to plan for than a little dizziness. Ketamine can cause heavy sedation, slow breathing, change blood pressure, produce distressing mental effects and be misused. Bladder and urinary problems are reported too. If the clinician isn’t in the room, get a specific explanation of how the program handles those risks. [4]

A clinician needs your actual history

You’ll find “good candidate” checklists everywhere, sometimes with a tidy number of failed antidepressants. That might be one program’s rule, not a rule for every ketamine product. Your history, other meds, blood pressure, drinking, drug use and previous treatments belong in the assessment. A checked box isn’t a substitute for someone doing that with you.

Questions worth asking before you start

Use these questions to find out who’s actually responsible for your care and what they’ll do. Reading the list isn’t a plan for keeping a session safe; the program needs to explain its own plan.

• Ask how they screened you, and whether anybody covered substance use, any history of psychosis or mania, blood pressure, pregnancy, and the other meds you take, especially sedatives or opioids.
• Ask who checks your blood pressure, and when.
• Ask what follow up looks like and how often an actual human talks with you.
• Ask who you contact if something goes wrong during or after a dose, and how fast somebody answers.
• Ask how you’ll decide together whether it’s working, and what happens if it isn’t.
• Ask what exactly is in the product and which pharmacy makes it.

Don’t start until you’ve got specific answers and know who’s responsible for your care. You shouldn’t need a crisis to find out who answers the phone.

Sources

1. Mathai DS et al., 2024. Home ketamine treatment for depression with telehealth support, findings from real world data. PubMed 38810787.
2. Rolan P et al., 2014. The absolute bioavailability of racemic ketamine from a novel sublingual formulation. PubMed 24977293.
3. Spravato (esketamine) nasal spray prescribing information. DailyMed label updated September 22, 2026. Indications, limits and supervised monitoring.
4. FDA, October 2023 alert on potential risks of compounded ketamine, archived capture from May 2026 linked from FDA’s compounding risk alerts index. Archived FDA alert.
5. FDA, Understanding the risks of compounded drugs. FDA page.
6. Berman RM et al., 2000. Antidepressant effects of ketamine in depressed patients. PubMed 10686270.